Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VERSED vs A/T/S
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Benzodiazepine that enhances GABA-A receptor activity, increasing chloride ion conductance and causing neuronal hyperpolarization.
A/T/S (erythromycin) is a macrolide antibiotic that acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and bacterial growth.
Sedation,Anxiolysis,Amnesia,Induction of anesthesia,Maintenance of anesthesia,ICU sedation,Status epilepticus (off-label)
Treatment of acne vulgaris (FDA-approved indication),Treatment of bacterial infections caused by susceptible organisms (off-label use for acne is the primary use)
IV: Initial 1-2.5 mg; titrate by 0.5-1 mg every 2-3 min; usual total 2.5-5 mg for sedation. IM: 0.07-0.08 mg/kg (max 5 mg) once. Oral: 7.5-15 mg once (preoperative).
Dosing is individualized based on antithrombin activity level. For acute thrombotic events: initial bolus of 30-50 IU/kg followed by maintenance dosing to achieve target activity levels (80-120% of normal). Prophylaxis: 40-60 IU/kg every 24 hours.
Terminal elimination half-life: 1.8–2.5 hours in healthy adults; prolonged in elderly (up to 6 hours), obesity (up to 8 hours), hepatic cirrhosis (up to 20 hours), and critically ill patients.
Terminal elimination half-life: 1–2 hours (prolonged in hepatic impairment).
Hepatic via CYP3A4 isoenzymes; major metabolites include midazolam glucuronide (inactive) and alpha-hydroxymidazolam (active).
Antithrombin is a glycoprotein; its metabolism involves cellular uptake and catabolism, but specific CYP450 enzymes are not involved. Degradation occurs via proteolysis and reticuloendothelial system clearance.
Renal: ~1% unchanged; Hepatic metabolism to glucuronide conjugates and 1-hydroxymidazolam, with subsequent renal elimination of metabolites. Fecal excretion is minimal (<2%).
Renal: 10-20% (active drug and metabolites); Fecal: minimal; Biliary: not significant.
97% bound primarily to albumin.
70-90% bound to serum albumin.
1–1.5 L/kg (0.5–1.2 L/kg in adults); increased in obesity and hepatic disease, indicating extensive tissue distribution.
0.5–0.8 L/kg (low Vd, minimal tissue penetration).
IM: 90%±; Oral: 40–50% (range 30–70%); Intranasal: ~75%; Rectal: ~50%.
Topical: 1–5% (minimal systemic absorption).
e GFR 10-50 m L/min: No dose adjustment needed but monitor for prolonged sedation. e GFR <10 m L/min: Consider 50% dose reduction and monitor closely.
No specific adjustment required; drug is not renally eliminated.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Avoid use or reduce dose by 75%.
No specific adjustment; antithrombin is produced in the liver, but exogenous replacement does not require dose adjustment in hepatic impairment.
Neonates: IV 0.05-0.1 mg/kg; max 0.15 mg/kg. Children: IV 0.025-0.05 mg/kg (max 2 mg); titrate. Oral 0.25-0.5 mg/kg (max 20 mg) for sedation. IM 0.07-0.08 mg/kg.
Dosing based on weight and antithrombin levels; typical initial dose 30-50 IU/kg, followed by maintenance to achieve target levels. Clinical trial data limited in neonates.
IV: Initial 0.5-1 mg over 2 minutes; titrate slowly; max total dose 3.5 mg. Oral: 5 mg preoperatively. Reduced clearance necessitates careful titration.
No specific adjustment; use standard dosing with monitoring of antithrombin activity and bleeding risk.
Intravenous administration may cause respiratory depression and arrest, especially when used with opioids. Resuscitation equipment and skilled personnel must be available. Do not administer by rapid bolus injection.
None.
Respiratory depression, hypotension, paradoxical reactions, dependence and withdrawal, use in elderly or debilitated patients, hepatic/renal impairment, myasthenia gravis, glaucoma, pregnancy (category D).
Hypersensitivity reactions including anaphylaxis have occurred.,Prolonged use may result in overgrowth of nonsusceptible organisms including fungi.,Use with caution in patients with hepatic impairment.,Potential for QT prolongation and ventricular arrhythmias, especially with intravenous administration or concomitant drugs that prolong QT interval.
Known hypersensitivity to benzodiazepines, acute narrow-angle glaucoma, severe respiratory insufficiency (COPD), pregnancy (labor and delivery), breastfeeding (caution).
Hypersensitivity to erythromycin or any macrolide antibiotic.,Use with caution in patients with pre-existing QT prolongation or electrolyte abnormalities (relative contraindication).
Grapefruit juice inhibits CYP3A4 and can significantly increase midazolam plasma concentrations, prolonging sedation and respiratory depression. Avoid grapefruit products for at least 24 hours before and after administration. High-fat meals may reduce absorption rate but not extent, though clinical significance is minimal.
No specific food interactions. Avoid excessive alcohol consumption as it may increase skin dryness.
Midazolam is classified as FDA Pregnancy Category D. There is evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans. First trimester exposure may be associated with an increased risk of congenital malformations (e.g., cleft palate). Second and third trimester exposure may cause fetal CNS depression, respiratory depression, and withdrawal symptoms (floppy infant syndrome). Use during labor may cause neonatal respiratory depression and hypotonia. Maternal hypotension and decreased uterine blood flow may occur.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; no adequate human studies in first trimester. Topical erythromycin has minimal systemic absorption; risk to fetus is low across all trimesters.
Midazolam is excreted in human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.05 to 0.15. Relative infant dose is estimated to be <1% of maternal weight-adjusted dose. Due to potential for accumulation and CNS effects in the neonate, caution is advised; alternative agents with shorter half-lives and no active metabolites are preferred. Use only if clearly needed and monitor infant for sedation, poor feeding, and respiratory depression.
Compatible with breastfeeding. Erythromycin is excreted into breast milk in small amounts (M/P ratio approximately 0.5). Topical use results in negligible systemic exposure; unlikely to cause adverse effects in nursing infants.
No specific standardized dose adjustments are established for pregnancy. Due to increased volume of distribution and altered protein binding, higher or more frequent doses may be required to achieve the same clinical effect. However, increased sensitivity to CNS depression and respiratory depression in pregnancy may offset this, requiring careful titration. Avoid use in first trimester if possible. Use lowest effective dose for shortest duration. During labor, use reduced doses due to potential for fetal accumulation and neonatal respiratory depression.
No dose adjustment required. Systemic absorption from topical application is minimal and not significantly altered by pregnancy-related pharmacokinetic changes.
Midazolam (Versed) is a short-acting benzodiazepine used for procedural sedation, pre-anesthetic medication, and status epilepticus. It has amnestic properties. Onset is rapid (1-2 min IV, 15-30 min IM). Flumazenil is the reversal agent. Caution in elderly, hepatic impairment, and respiratory compromise. CYP3A4 inhibitors (e.g., macrolides, azole antifungals, grapefruit juice) increase levels. Not recommended for prolonged sedation in ICU due to active metabolites and accumulation.
A/T/S (erythromycin 2% topical solution) is indicated for acne vulgaris. Avoid contact with eyes, mouth, and mucous membranes. May cause skin dryness or irritation; use moisturizer. Effectiveness may decrease with prolonged use due to bacterial resistance. Not recommended for use with other topical erythromycin products or clindamycin to avoid antagonism.
You may experience drowsiness, dizziness, or amnesia after receiving this medication.,Do not drive or operate heavy machinery for at least 24 hours after the procedure.,Avoid alcohol for at least 24 hours after receiving midazolam.,Grapefruit and grapefruit juice may increase the effects of midazolam; avoid consumption.,Inform your healthcare provider if you are pregnant, breastfeeding, or have a history of glaucoma or breathing problems.
Apply a thin layer to affected areas twice daily after washing.,Avoid contact with eyes, lips, and mouth; if contact occurs, rinse thoroughly with water.,May cause stinging, burning, or peeling; if irritation persists, consult your doctor.,Use sunscreen daily as this medication may increase sensitivity to sunlight.,Do not use more than prescribed; overuse may increase side effects without improving results.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Keep away from open flames or heat sources; product is flammable.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VERSED vs A/T/S, answered by our medical review team.
VERSED is a Benzodiazepine that works by Benzodiazepine that enhances GABA-A receptor activity, increasing chloride ion conductance and causing neuronal hyperpolarization.. A/T/S is a Macrolide antibiotic that works by A/T/S (erythromycin) is a macrolide antibiotic that acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and bacterial growth.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VERSED and A/T/S depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VERSED is: IV: Initial 1-2.5 mg; titrate by 0.5-1 mg every 2-3 min; usual total 2.5-5 mg for sedation. IM: 0.07-0.08 mg/kg (max 5 mg) once. Oral: 7.5-15 mg once (preoperative).. The standard adult dose of A/T/S is: Dosing is individualized based on antithrombin activity level. For acute thrombotic events: initial bolus of 30-50 IU/kg followed by maintenance dosing to achieve target activity levels (80-120% of normal). Prophylaxis: 40-60 IU/kg every 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VERSED and A/T/S in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VERSED is classified as Category C. Midazolam is classified as FDA Pregnancy Category D. There is evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in. A/T/S is classified as Category C. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; no adequate human studies in first trimester. Topical erythromycin has minimal systemic absorption; risk . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.